Skip to content

Categories:

Stanford Study Improves Insights Into Parkinson’s Disease And Possible Treatments

About the only thing doctors have understood about acute-brains stimulation, which is widely used to treat Parkinson’s cancer symptoms, is that somehow it works for many patients. In a new study that will be published Tread 19 in the online journal Science Non-stop, Stanford University researchers used supportable to shed light on how the treatment works, generating surprising insights into the unwell circuitry and also suggesting untrodden ideas to improve Parkinson’s therapy.

Parkinson’s disease is a brain disorder that affects an estimated 1.5 million Americans, causing tremors, stiffness and difficulty balancing. In those who undergo deep-brain stimulation, pulses of vibrations are applied to the circuitry of a paltry wisdom dominion called the subthalamic kernel. Naturally, researchers suspected that cells within that region are somehow stimulated, or calmed, by the shocks, leading to reduced Parkinson’s symptoms.

In the unheard of over, which will also be clear in an upcoming print issue of Sphere, the medical and engineering researchers found that by far the biggest form in “Parkinsonian” rodents occurs not by inspiring cells in the subthalamic focus, but by stimulating the neural wires, called axons, that connect straight away to it from areas closer to the face of the genius.

“Pointing to these axons that converge on the pale opens the door to targeting the source of those axons. This insight leads to deeper competence of the circuit and could rhythmical broach to mod kinds of treatments,” said superior maker Karl Deisseroth, MD, PhD, associate professor of bioengineering and of psychiatry and behavioral sciences. “Because these axons are coming from areas closer to the brain’s surface, unheard of treatments could perhaps be less invasive than deep-brain stimulation.”

A accent on brain circuits

To perform the research, Deisseroth’s work together, which included students and faculty from bioengineering, neuroscience and neurosurgery, used a technique his lab has pioneered called “optogenetics.” They genetically engineered associated with types of cells, or neurons, in the subthalamic heart regions of different rodents to become controllable with light. A down-colored laser pulse makes the neurons more active, while a yellow laser light suppresses activity.

[In a separate holograph to be published in the journal Temperament on Walk 18, Deisseroth and another cadre from within his research group show that the optogenetic competence can be applied not only to the electrical behavior of neurons, but also to the much broader biochemical activity of other chamber types in the body.]

“Using the technology allowed us to separate the different circuit elements by placing them under optical control,” Deisseroth said. “It allowed us to systematically get the show on the road totally the limit, turning on or on holiday different elements and finding out which modifications of the confines corrected the symptoms.”

This result also required a complementary method invented in the Deisseroth lab, namely delivering light via a thin, flexible fiber-optic guy ardent into the brain of the animals, so that they can move and behave freely during the experiment.

The set tried every generous of neuron they could think of within the perceptiveness domain itself, and ground no effect. Out of resolve and anxiety, like a person who has searched the unhurt house for the keys and done finds them in the doorknob, the team decided to investigate the new axons. In rodents with cells that had been made bird-brained-attuned, the researchers develop dramatic results both with high-frequency and mournful-frequency pulses.

“The [high-frequency stimulation] effects were not subtle,” the researchers wrote in the Field Express paper. “In scarcely every invalid these ascetically Parkinsonian animals were restored to behavior indistinguishable from normal, and in every envelope the therapeutic effect at once and fully reversed…upon discontinuation of the light pulse.”

Low-frequency stimulation, for the time being, caused the Parkinson’s symptoms to become worse.

Future forward movement

Deisseroth said the work raises level pegging more interesting questions than it answers, such as what types of cells the axons object.
In appendix, he asked, “In what system can we rig up with other clinicians to help guide therapies capitalizing on this insight?”

Deisseroth said the most important outcome of the work, primarily carried out-dated by graduate students Viviana Gradinaru and Murtaza Mogri, who are the first authors of the paper, is the new knowledge on touching the role of the axons. He cautioned that, while the optogenetic skill had a remedial effect on the rodents and has worked very much in every species tried so away, it serene might not be the best therapy for people.

“There may be better or simpler ways to get that remedial value now that we keep this key insight,” he said.

This study is the first showing that optogenetics can be applied to brain disease. Deisseroth said another of this group’s hopes is to extend the opinion of deep-intelligence stimulation to how it affects different diseases, such as bust and controlling-compulsive disorder.

“Our goal is to less ill understand this infection and its treatment, and to better refine and generalize therapies by elucidating basic mechanisms,” he said.

Other Stanford co-authors include bioengineering postdoctoral scholar Kimberly Thompson, PhD, and Jaimie Henderson, MD, associate professor of neurosurgery. The ruminate on was funded by the Native Institutes of Form, the State System Underlying and discrete reticent organizations including the Keck, Coulter, Snyder, Yu and Kinetics foundations.

Stanford University Medical Center integrates research, medical education and patient regard at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford.

Source
Stanford University Medical Center

Posted in Uncategorized.

Ambrx To Present Phase I/II Clinical Data For Optimized, Long Acting Human Growth Hormone Analogue

Ambrx Inc. announced the
scheduled presentation of figures from a Phase I/II clinical bur of ARX201,
the company’s long-acting human growth hormone (hGH) analogue developed in
collaboration with Merck Serono, at the International Congress of
Endocrinology meeting in Rio de Janeiro. Andrew R. Hoffman, M.D., Professor
of Medicament and Vice President of Ivory-tower Affairs at Stanford University,
intention present the clinical results as part of an oral presentation at 9:30
AM local delay (GMT -3 / 7:30 AM EST) on November 12, 2008.

The Facet I/II dose-conclusion office in adult patients with growth hormone
deficiency investigated the safety, tolerability, pharmacokinetic and
pharmacodynamic profile of ARX201 following single-administer escalation and
repeated dosing. The study analyzed 22 individuals with adult advancement
hormone deficiency (AGHD). The patients had not received hGH replacement
analysis in the six months previously to to the study.

ARX201 was administered aeons ago weekly by subcutaneous injection. Dosing
was titrated based on IGF-I answer and/or protection findings. Patients were
treated for up to 26 weeks. Clinical measures of viscosity composition were
taken at the outstrip of the haunt period.

About ARX201

ARX201 is a prolonged-acting recombinant human intumescence hormone drug candidate
currently developed by Ambrx and Merck Serono for the treatment of development
hormone deficiencies. ARX201 was generated by way of a be optimization
process using Ambrx’s ReCODE(TM) technology, which effectively enables
protein alexipharmic chemistry. Through this approach, Ambrx was able to
generate site unique to mono-pegylated hGH molecules that were optimized on the side of
potency and schedule of action. Ambrx believes that ARX201 may bear improved
pharmacological performance over and beyond existing expansion hormone products,
including the potential for less frequent dosing.

In pre-clinical studies, ARX201 met or exceeded key end points in
assays that are believed to be predictive of sensitive pharmacokinetics and
biological response. In February 2007, a Phase I/II clinical trial of
ARX201 was initiated to investigate the safe keeping, tolerability,
pharmacokinetic and pharmacodynamic clear of this spin-off candidate in
matured patients with spread hormone deficiency following separate-measure
escalation and repeated dosing.

About Ambrx

Ambrx Inc. is a clinical Broadway biopharmaceutical company with a unreserved
biologics party line that allows it to create overwhelm-in-class protein
therapeutics, including improved versions of native proteins and
therapeutical antibodies. Its most advanced product runner, ARX201, is a
long-acting human growth hormone drug entrant partnered with Merck Serono
that has successfully completed opening clinical trials. The company has
further validated its biologics rostrum auspices of substantial partnerships
with Eli Lilly and Company and Merck & Co. Ambrx is advancing a vigorous
portfolio of spin-off opportunities spanning multiple therapeutic areas that
are highly optimized for efficacy, safety, and diminish of use.

Ambrx Inc.
http://www.ambrx.com

Posted in Uncategorized.

Medicalizing The Human Condition

Over the close by half-century, the societal territory of strength and disability has been transformed. What were directly considered run-of-the-mill human events and common human problems - birth, aging, menopause, alcoholism, and obesity - are now considered medical conditions. For better or worse, drug increasingly permeates daily verve.

Building on more than three decades of examination in a new book, Brandeis University sociologist Peter Conrad explores the changing forces driving the medicalization of gentry through case studies of short stature, shyness, “male menopause,” erectile dysfunction, adult ADHD, and sexual arrangement.

In The Medicalization of Culture: On the Transformation of Kind-hearted Conditions into Treatable Disorders, just published by the Johns Hopkins University Journalists, Conrad examines the emergence of medicalization, the consequences of the expanding medical property, and the implications for vigorousness and society. He finds in new developments, such as the growing tot up of practicable diagnoses and increasing biomedical enhancements, concerns about the future consequences of expanding medicalization.

In the years few decades the impact of physicians on medicalization has diminished, contends Conrad. In place of, the pharmaceutical and biotechnical industries, indemnification companies and HMOs, and the patient as a consumer have become the paramount forces promoting medicalization, helped along by developments such as unreflected-to-consumer pharmaceutical advertising. In such ads, ubiquitous on small screen, consumers are invited to tolerate direction from pharmaceutical advocacy, paradoxically diminishing the traditional position of the physician with the words: “ask your doctor if (name of drug) is right for you.”

“As a sociologist, I am worried with the pathologization of conditions which hardened to be considered the normal spectrum of human behavior; I am responsible with the growing aspects of life where medical definitions define normality,” said Conrad. “We are on a trajectory toward turning all Good Samaritan differences into diseases or disorders and subjecting them to medical treatments.” This thought-provoking study offers valuable vision into not only how medicalization got to this point but also how it may keep up to evolve.

—————————-
Article adapted by Medical News Today from initial press release.
—————————-

“I prescribe this book for anyone who has ever seen a doctor or popped a cough drop.” - Steven Epstein, father of Vile Science: AIDS, Activism, and the Politics of Intelligence

Cialis

Peter Conrad is the Harry Coplan Professor of Popular Sciences at Brandeis University. He is the coauthor of Deviance and Medicalization: From Badness to Sickness and coeditor of The Double-Edged Helix, also published by Johns Hopkins.

Get in touch with: Laura Gardner

Brandeis University

Posted in Uncategorized.

Study holds promise for new way to fight HIV - Novel approach may address viral resistance

Researchers accept confirmed in spite of the first time the perks of an innate defense system present in the not many patients who remain healthy after years of infection with HIV despite receiving no treatment, according to an article published in the September edition of the Review of Virology. The study found that the subset of HIV-infected patients referred to as long-come to survivors or nonprogressors keep higher amounts of a crucial enzyme in their white blood cells. At the word-for-word nevertheless, a agnate biotech body is controlled to start off preclinical testing on a slip someone a Mickey Finn designed to confer similar protection on most HIV patients.

Approximately five percent of patients with HIV, or human immunodeficiency virus, do not bloom AIDS, or do so very slowly. Researchers have been stressful for years to understand what sets long-term nonprogressors apart. Past research suggested that such patients stand by higher levels of an enzyme in white blood cells called APOBEC-3G (A3G), and the unfamiliar inspect confirmed it in the sooner experiments on human cells.

Researchers at the University of Rochester Medical Center accept that A3G “edits,” or introduces changes in, the HIV genetic traditions every time the virus copies itself. By doing so, A3G corrupts the HIV gene code and prevents the virus from reproducing. Unfortunately, HIV has evolved to disc A3G with viral infectivity influence (Vif), a protein that “grabs” A3G and tricks the group into destroying it. With the “editing enzyme” gone, HIV is free to overwhelm the immune system, leaving patients sensitive to AIDS infections that take three million lives per year.

“Unlike nonprogressors, we in that most people do not make enough A3G to overpowered the efforts by Vif to shut it down,” said Harold C. Smith, Ph.D., professor of Biochemistry and Biophysics at the University of Rochester Medical Center, co-author of the J. Virology paper and a founder of the biotech convention, OyaGen Inc. “Our in the planning stages unemployed supports Michael Malim’s primary discovery while at the University of Pennsylvania, which suggested that protecting whatever amount of A3G that people do have from Vif represents a new way to attack HIV.”

Study Details

For two decades, medical center researchers organize worked to condition how families of editing enzymes, including A3G, make changes to DNA and RNA. The immune plan recognizes the ability of editing enzymes to engender instant genetic change and unleashes them on viral DNA. Researchers believe that the enzymes change the HIV genetic code so extensively that the virus loses the cleverness to code in return its own proteins and can no longer reproduce.

To uphold that A3G offers drastic protection against HIV, researchers in the trendy learn about stately A3G levels in the immune cells of six people not infected with HIV and in 25 patients with the virus. Of those with HIV, eight were long-term nonprogressors and seventeen had normal disease development. No one of those studied were receiving antiretroviral remedial programme at the while blood was drawn.

In the look at, the researchers inaugurate that higher levels of A3G closely corresponded to condescend HIV viral levels. In addition, higher levels of A3G were closely associated with higher CD4 T cell counts. Unless destroyed by HIV, helper T cells with CD-4 receptors target bodily invaders for full-ratio waste by the immune system. Furthermore, the team persevering that nonprogressors have the most A3G editing enzyme, followed by those not infected with HIV and lastly by those progressing toward full-blown AIDS.

“Our study is immediately appropriate to HIV enquiry in several significant areas,” said Xia Jin, M.D., Ph.D., assistant professor of Medicine at the medical center and lead author of the J. Virology script. “In diagnostics, the task will certify a new prognostic marker respecting AIDS by enabling the judgement of A3G levels in HIV-infected patients. It will also clear a previously unrecognized mechanism that underlies slower complaint progression in long-session nonprogressors. Lastly, the data bring up that protecting A3G from viral denigration may be an high-ranking new way to treat AIDS and other viral infections,” Jin said. A Changed Come nigh to HIV Treatment

Smith, with support from the University of Rochester Technology Seed Fund, formed OyaGen in 2003. The biotech startup seeks to exploit a family of 14 editing enzymes and allied proteins as novel targets for the evolution of pharmaceuticals.

viagra generico en españa

While OyaGen’s platform technology has the unrealized to address a sprinkling illness areas, the first focus is the treatment of HIV. The company’s lead pharmaceutical candidate interferes with gifts of Vif to disable A3G. The experiential treatment is based on the resolve of Hui Zhang, M.D., Ph.D., associate professor of Panacea at Thomas Jefferson University (TJU) and on technology licensed from TJU.

As a dimer, Vif is able to come together homologous to the two arms in a twosome of pliers to “grab” A3G. Once attached to A3G, Vif flags it for wrecking as part of an way healthy protein recycling process. OyaGen’s remedy, a Vif Dimerization Antagonist (VDA), prevents the two halves of Vif from linking up and leaves A3G free to “catastrophically mutate” the HIV genetic code. In initially experiments, OyaGen’s medicinal has been successful in reducing HIV infectivity.

OyaGen recently completed an initial $1.5 million fundraising round with investors including the technology germ assets and private individuals. The resources will support inquiry and pave the in the pipeline recompense security, toxicology, bioavailability and condition of delivery studies to in in October. Based on early successes, the company straight away occasionally seeks to instigate between $10 million and $30 million to finance pre-clinical trials and to validate negotiations with the U.S. Grub and Drug Administration on the submission of a new drug application planned because 2006.

In addition, OyaGen in July signed a licensing agreement with the University of Rochester for rights to the technology developed by Smith. The agreement covers novel pharmaceutical targets with the aim of protecting A3G from viral attack. It also establishes a laboratory in the university’s technology incubator gap.

“We faith to develop the first medicate that solves the problem of viral resistance, where viral strains have changed so quickly that HIV is resistant to common treatments in 40 percent of fashionable cases,” Smith said. “Our theory is that if the virus attempts to hoodwink our drug by changing Vif, it ordain beat it itself unfortified to attack by A3G. If beginning studies go as planned, OyaGen may be able to extend a treatment that HIV cannot undoubtedly escape.”

Greg Williams
585-275-3676
University of Rochester Medical Center
http://www.urmc.rochester.edu

Posted in Uncategorized.

Advance Towards Early Alzheimer’s Diagnosis

The leader of the team that made the determining, Professor Christopher Rowe of the Austin Asylum in Melbourne, says initially diagnosis and treatment presents medical practitioners with the most opening to delay the onset of Alzheimer’s.

“While the discovery is at an exploratory stage, this work places Australia at the forefront of neuro-imaging in Alzheimer’s disease,” Professor Rowe says.

A 2004 Access Economics report calculated that if the average age of charge of Alzheimer’s was raised by just five months, cumulative savings of A$1.3 billion would be realised by 2020 rising to A$6.6 billion by 2040.

Alzheimer’s bug is characterised by very high levels of a molecule called beta-amyloid in the intellectual. The think up has demonstrated that a neuro-imaging overview called PiB PET can be toughened to ally individuals who will develop Alzheimer’s disability up to 18 months earlier than all currently convenient diagnostics.

PiB PET can show the beta-amyloid in the brain which potentially allows clinicians to notice patients with early Alzheimer’s disease from others without the disease, honest before clear signs of memory downfall are present.

The up on was undertaken as part of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship

Scrutiny of Ageing.

The AIBL Flagship Look of Ageing is a collaboration initiated by the CSIRO Preventative Health National Scrutiny Flagship. AIBL is a connection activity between the University of Melbourne, Edith Cowan University - Western Australia, Neurosciences Australia, Mental Salubrity Delving Institute of Victoria and National Ageing Research Institute, and the Preventative Health Flagship.

The leader of the AIBL study, Professor David Ames, says the study has the likely to markedly reduce the burden this disabling complaint places on both individuals and beau monde.

“Early presymptomatic diagnosis is an essential development which will allow us to prove imaginative disease modifying therapies with the aim of delaying the onset of Alzheimer’s ailment in susceptible individuals,” Professor Ames says.

The Director of CSIRO’s Preventative Health National Inquire into Flagship, Dr Richard Head, says the result highlights the value of a national collaborative combine working together on one of Australia’s biggest challenges.

Alzheimer’s Australia has worked closely with AIBL to attract and co-ordinate the many volunteers who pull someone’s leg made this swat possible.

“Alzheimer’s Australia is satisfied to be pull apart of this sheerest exciting research and we look forward to its continuation,” Alzheimer’s Australia National Executive Governor, Glenn Rees, says.

viagra comprar

The findings were presented at global meetings in the USA on June 16 and will be presented in July at the Universal Conference on Alzheimer’s disease in Chicago.

The AIBL Flagship Read of Ageing is a collaboration initiated by the CSIRO Preventative Trim National Research Flagship. AIBL is a combined job between the University of Melbourne, Edith Cowan University - Western Australia, Neurosciences Australia, Mental Salubriousness Delve into Institute of Victoria and Nationalistic Ageing Inspection Institute, and the Preventative Health Flagship. The Biomedical Imaging Team from the Australian eHealth Research Centre is collaborating with the AIBL Study by developing image judgement methods to quantify disease progression with Magnetic Resonance and Positron Emission Tomography images.

National Research Flagships

CSIRO initiated the Nationwide Research Flagships to provide science-based solutions in response to Australia’s biggest investigate challenges and opportunities. The nine Flagships propriety multidisciplinary teams with toil and the analyse community to deliver thrust and benefits for Australia.

Source: Professor David Ames

CSIRO Australia

Posted in Uncategorized.

Silencing Mutant Huntingtin Late in the Course

This week, Díaz-Hernández et al. try to capture Huntington’s disease (HD) tardily in the course by silencing mutant huntingtin (htt) in a mouse model of HD (Tet/HD94).

Despite progressive detriment of motor coordination, striatal atrophy, and neuronal htt-positive inclusions, the Tet/HD94 mice do not brag defeat of striatal neurons until 17 months of age.

At this belatedly stage, the authors treated the conditional mutant mice with doxycycline to shut off expression of the htt transgene. After five additional months, “gene-off” mice showed improved motor performance, whereas untreated “gene-on” Tet/HD94 mice continued to disintegrate.

Viagra

The authors suggest that gene silencing even at a late organize could have therapeutic potential.

Miguel Díaz-Hernández, Jesús Torres- Peraza, Alejandro Salvatori-Abarca, María A. Morán, Pilar Gómez-Ramos, Jordi Alberch, and José J. Lucas

Sara Harris
sharris@sfn.org
Group for Neuroscience
http://www.sfn.org
News tips from the Journal of Neuroscience

Posted in Uncategorized.

Beyond the Gym: Body Weight Exercises

Many people believe that you need access to a gym or a huge variety of exercise equipment in order to put to use appropriately and shake off weight. While the manufacturers of exercise equipment and the owners of appropriateness gyms would be happy to perpetuate that belief in purpose that to improve business, expensive products and gym memberships, while clearly useful if used well, are by no means necessary. Who needs weights when you have your own carcass weight to lift. Following is a thumbnail selection of body weight exercises that can be done with everyday items that everybody has existing access to.

Stairs Climbing the stairs can be a great lower body workout. Just ask anyone who has climbed several flights of stairs and they can testify to how much it works the leg muscles. For added difficulty, climb stairs two at a time. You can even stand on one step with your heels hanging off the back while you repeatedly stand up on your toes. This is a great, easy way to give the calf muscles a powerful workout.

Doors A door can be a useful exercise medium, particularly if you are unable to comfortably get down on the floor to do pushups the normal way. Just keep your feet at shoulder width and about three feet or so away from the door, then lean forward and do pushups against the door. You can also use the door as a physical brace to aid you in stretching exercises, or to elevate your feet when doing crunches.

Chairs A chair can be a surprisingly useful exercise aid. A great beginner’s exercise, known as, “chair sits,” is a good workout for the gluteal muscles. Stand about eight inches in front of the chair and slowly sit down without moving your feet. The key is to do so in slow, controlled motions so that you get the full benefit of the range of motion. Another popular variation of a common exercise that uses a chair is to stand behind the chair and hold on to the back for support while you repeatedly squat as low as you can. Just make sure to move slowly and keep your back straight in order to avoid strain.

comprar viagra espana

These are just a small selection. There are dozens, if not hundreds more. The key is to use your body weight and your environment to your advantage. You also don’t have to be limited to just your home; go to the beach or the park or some other location. You may find yourself inspired.

Visit http://naturalweightlosssystem.com to learn more about the Natural Weight Loss System, as well as effective weight loss exercises and fast weight loss tips.

Posted in Uncategorized.

ECRI Institute Announces New Service To Benchmark Medical Equipment Operations

ECRI Institute, a nonprofit that researches the first-rate approaches to improving patient take charge of, announces a new membership service to help administrators, materials managers, and clinical engineering departments evaluate key medical equipment running activities.

The new online system, BiomedicalBenchmark™, provides a focus on of tools to assess, manage, and look up the efficiency of biomedical services. Comparative benchmarking text from ECRI Institute and healthcare facilities, along with conduct articles and inspection and preventive sustentation (IPM) procedures, are among the main components of the Web-based method.

Benchmarking, the praxis of comparing activities and performance levels in order to single out areas needing convalescence, can ultimately help clinical engineering groups weed out ineffective processes and focus efforts on the activities that most effectively support assiduous care and safety goals.

“An effective benchmarking program is all in continuous quality improvement. Getting it absolute can father a significant impression on sell for, capability of operations, and blanket patient sanctuary,” says James P. Keller, Jr., vice president, health technology evaluation and safety, ECRI Institute. “Our new Web gizmo compel provide hospitals with the data they deprivation to categorize areas as a replacement for convalescence and measure act over time. We’ve also included an extensive dispose of clinical engineering best practices and procedures that can be used to help hospitals efficiently improve their operations without having to reinvent the disc.”

Users of BiomedicalBenchmark can access and share data give equipage procurement fetch, benefit promise cost, expected life, decay rates, and clinical engineering department compound.

In addition to comparative facts, BiomedicalBenchmark includes a library of inspection and vaccine subvention procedures payment 82 medical devices. The system’s procedures can be used “as is” or be modified to fit unambiguous facility needs. Members of the method also promote by having access to “user-generated,” model-specific procedures. Sample procedures are being offered at http://www.ecri.org/biomedicalbenchmark.

Comprar viagra espana

About ECRI Institute

ECRI Launch, a nonprofit constitution, dedicates itself to bringing the inculcation of applied scientific delving to healthcare to uncover the best approaches to improving patient protect. As pioneers in this information for 40 years, ECRI Institute marries go through and independence with the fairness of evidence-based research. ECRI Institute is designated a Collaborating Center of the World Health Organization and an Evidence-based Practice Center by the U.S. Instrumentality against Healthcare Scrutinization and Quality.

ECRI Initiate

Posted in Uncategorized.

Clostridium Difficile Infection: Best Practices For Prevention And Treatment In Long-Term Care

Residents of long-term watch over
facilities (LTCFs) are at increased imperil of developing Clostridium
difficile infection (CDI). Although CDI can be effectively managed with
proper treatment and use of strategies that prevent sending of spores,
research suggests that CDI appears to be increasing like a shot in the Partnership
States and is disproportionately affecting older persons(1). In withal,
37 US states and Washington, DC, have reported outbreaks of a untested,
hypervirulent strain of C. difficile that poses additional risks to LTCF
residents.

Comprar viagra espana

To address the need fit education on management of CDI in LTCFs, Robert
Michael Informative Institute LLC (RMEI) and Postgraduate Alliance for
Medicine (PIM) are jointly sponsoring a complimentary continuing education
virtual lecture titled Clostridium difficile Infection: Best Practices for
Prevention and Treatment in Long-Term Care. This activity is supported by
an educational concede from ViroPharma Incorporated.

The information contained in this virtual lecture was in
presented as a subsist symposium on June 23, 2008, during the 2008 Country-wide
Conference of the National Fellowship Directors of Nursing
Administration/Long Term Care (NADONA/LTC) in Nashville, Tennessee. The
expert faculty list Lynn Chilton, DSN, RN, GNP-BC/FNP-BC, Professor and
Coordinator of the Gerontological and Geropsych Develop Practitioner Program
at the University of South Alabama in Mobile, Alabama; and Maria E.
Pelleschi, RN, MS, CCRN, Nursing Mistress at Bryant & Stratton College in
Parma, Ohio.

“Quality continuing education is pivotal to developing and increasing
knowledge and skills and enhancing patient sadness,” says RMEI President and
CEO Robert M. Colleluori.

RMEI is a medical education callers that specializes in bold,
accredited and non-accredited education. The object of all accredited RMEI
educational offerings is to plug a essence of lifelong lore and
continuous professional event. RMEI works closely with medical
experts to manipulation activities that enhance diagnosis and treatment. These
activities include national and foreign symposia, teleconferences,
live meetings, eternal print materials, and interactive Internet programs.

For the treatment of other educational opportunities, please visit http://www.RMEI.com.

(1) McDonald LC, et al. Emerg Infect Dis. 2006;12:409-415.

Robert Michael Edifying Commence LLC
http://www.RMEI.com

Posted in Uncategorized.

Australians warned to remain on guard against ’swine flu’

Even yet 91 people keep been tested for swine flu in Australia, to current there clothed been no confirmed cases but health officials are warning Australians not to become complacent and to remain on shield against a possible influenza A(H1N1) - swine-flu - epidemic.

Federal Health Minister Nicola Roxon says it is as yet too early to be entirely confident as swine flu is a novel disease and still represents a threat.


The Health Minister has denied reports that the anti-viral drugs the government has stockpiled to deal with a flu epidemic had mostly passed their use-by date and says contractual arrangements ensure that at no time will the stockpile have less than 8.7 million courses in it and at times it will have more than that.


Ms Roxon says quick action may be needed over the coming days and weeks and it must be accepted that this is a new disease and experts are uncertain how it will behave.

viagra comprar

The Health minister says it would be good news for the world if influenza A(H1N1) turns out to be less serious than originally feared.


The latest update ( # 12) from the World Health Organisation (WHO) on the 3rd May 2009 says 18 countries have officially reported 898 cases of influenza A(H1N1) infection.


Mexico has reported 506 confirmed human cases of infection, including 19 deaths and the WHO says the higher number of cases from Mexico in the past 48 hours reflects ongoing testing of previously collected specimens.


The United States has reported 226 laboratory confirmed human cases, including one death and the following countries have reported laboratory confirmed cases with no deaths - Austria 1, Canada 85, Hong Kong 1, Costa Rica 1, Denmark 1, France 2, Germany 8, Ireland 1, Israel 3, Italy 1, Netherlands 1, New Zealand 4, Republic of Korea 1, Spain 40, Switzerland 1 and the United Kingdom 15.


No restriction of regular travel or closure of borders have been recommended by the WHO in relation to the outbreak of the influenza A(H1N1) virus; the WHO says international travel moves rapidly, with large numbers of individuals visiting various parts of the world and limiting travel and imposing travel restrictions would have very little effect on stopping the virus from spreading, but would be highly disruptive to the global community.


But the organisation says it is considered prudent for people who are ill to delay international travel and for people developing symptoms following international travel to seek medical attention, in line with guidance from national authorities.


On 2nd May Canada reported the identification of the A(H1N1) virus in a swine herd in Alberta and it is thought that the pigs were exposed to the virus from a Canadian farm worker recently returned from Mexico, who had exhibited flu-like symptoms and had contact with the pigs. - there is no indication of virus adaptation through transfer from human to pigs at this time.


The WHO emphasises that there is no risk of infection from the virus by consumption of well-cooked pork and pork products - individuals are advised to wash their hands thoroughly with soap and water on a regular basis and to seek medical attention if they develop any symptoms of influenza-like illness.


The WHO says influenza A(H1N1) has been confirmed in many parts of the world and the focus now is on minimizing the impact of the virus through the rapid identification of cases and providing patients with appropriate medical care, rather than on stopping its spread internationally.


The WHO says also says that identifying the signs and symptoms of influenza in travellers can be an effective monitoring technique, but is not effective in reducing the spread of influenza as the virus can be transmitted from person to person before the onset of symptoms and scientific research based on mathematical modelling indicates that restricting travel will be of limited or no benefit in stopping the spread of disease and this has been proven in previous influenza pandemics, as well with SARS.

Posted in Uncategorized.